BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20955692)

  • 1. Oncoproteomics.
    Joshi S; Tiwari AK; Mondal B; Sharma A
    Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative oncoproteomics strategies for anticancer drug discovery.
    Liu R; Wang K; Yuan K; Wei Y; Huang C
    Expert Rev Proteomics; 2010 Jun; 7(3):411-29. PubMed ID: 20536311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncoproteomics: current trends and future perspectives.
    Cho WC; Cheng CH
    Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance mechanisms in cancer cells: a proteomics perspective.
    Verrills NM; Kavallaris M
    Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of oncoproteomics in the personalized management of cancer.
    Jain KK
    Expert Rev Proteomics; 2004 Jun; 1(1):49-55. PubMed ID: 15966798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
    Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
    Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in oncoproteomics.
    Jain KK
    Curr Opin Mol Ther; 2002 Jun; 4(3):203-9. PubMed ID: 12139304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer: a proteomic disease.
    Li G; Xiao Z; Liu J; Li C; Li F; Chen Z
    Sci China Life Sci; 2011 May; 54(5):403-8. PubMed ID: 21455689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting cancer drug response by proteomic profiling.
    Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
    Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic approaches for the identification of cell cycle-related drug targets.
    Flory MR; Aebersold R
    Prog Cell Cycle Res; 2003; 5():167-71. PubMed ID: 14593710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of oncoproteomics to cancer biomarker discovery.
    Cho WC
    Mol Cancer; 2007 Apr; 6():25. PubMed ID: 17407558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.